AU725556B2 - Method for treating pain - Google Patents

Method for treating pain Download PDF

Info

Publication number: AU725556B2
Authority: AU; Australia
Prior art keywords: pain; treatment; olanzapine; drug useful; composition
Prior art date: 1996-03-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU25430/97A

Other languages

English (en)

Other versions

AU2543097A (en

Inventor

Harlan E Shannon

Daniel E. Womer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-25

Filing date

1997-03-24

Publication date

2000-10-12

1997-03-24 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

1997-10-17 Publication of AU2543097A publication Critical patent/AU2543097A/en

2000-10-12 Application granted granted Critical

2000-10-12 Publication of AU725556B2 publication Critical patent/AU725556B2/en

2017-03-24 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

208000002193 Pain Diseases 0.000 title claims description 141
230000036407 pain Effects 0.000 title claims description 140
238000000034 method Methods 0.000 title claims description 27
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 137
229960005017 olanzapine Drugs 0.000 claims description 136
238000011282 treatment Methods 0.000 claims description 108
239000003814 drug Substances 0.000 claims description 107
229940079593 drug Drugs 0.000 claims description 99
239000000203 mixture Substances 0.000 claims description 58
150000001875 compounds Chemical class 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 27
230000000202 analgesic effect Effects 0.000 claims description 26
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 25
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 22
239000012453 solvate Substances 0.000 claims description 18
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 17
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 16
229960001680 ibuprofen Drugs 0.000 claims description 15
-1 keoprofen Chemical compound 0.000 claims description 12
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 12
229960005181 morphine Drugs 0.000 claims description 11
229960001259 diclofenac Drugs 0.000 claims description 10
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 10
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 8
229960001138 acetylsalicylic acid Drugs 0.000 claims description 8
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 8
229960005489 paracetamol Drugs 0.000 claims description 7
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
229940123445 Tricyclic antidepressant Drugs 0.000 claims description 6
230000001800 adrenalinergic effect Effects 0.000 claims description 6
239000000730 antalgic agent Substances 0.000 claims description 6
229960002009 naproxen Drugs 0.000 claims description 6
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 6
208000004296 neuralgia Diseases 0.000 claims description 6
239000003029 tricyclic antidepressant agent Substances 0.000 claims description 6
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 5
238000002441 X-ray diffraction Methods 0.000 claims description 5
229940035676 analgesics Drugs 0.000 claims description 5
229940125681 anticonvulsant agent Drugs 0.000 claims description 5
239000001961 anticonvulsive agent Substances 0.000 claims description 5
208000021722 neuropathic pain Diseases 0.000 claims description 5
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 5
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 4
239000005557 antagonist Substances 0.000 claims description 4
229960004126 codeine Drugs 0.000 claims description 4
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
239000003772 serotonin uptake inhibitor Substances 0.000 claims description 4
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 3
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 3
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 3
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 3
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 3
229960002896 clonidine Drugs 0.000 claims description 3
229960001419 fenoprofen Drugs 0.000 claims description 3
229960002390 flurbiprofen Drugs 0.000 claims description 3
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 3
229940013798 meclofenamate Drugs 0.000 claims description 3
229960001797 methadone Drugs 0.000 claims description 3
230000003551 muscarinic effect Effects 0.000 claims description 3
229960002085 oxycodone Drugs 0.000 claims description 3
229960002702 piroxicam Drugs 0.000 claims description 3
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 3
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 3
229960000894 sulindac Drugs 0.000 claims description 3
229960001017 tolmetin Drugs 0.000 claims description 3
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 3
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 2
208000001294 Nociceptive Pain Diseases 0.000 claims description 2
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 2
239000003420 antiserotonin agent Substances 0.000 claims description 2
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
229960001736 buprenorphine Drugs 0.000 claims description 2
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims description 2
229960001113 butorphanol Drugs 0.000 claims description 2
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
229960000623 carbamazepine Drugs 0.000 claims description 2
230000001713 cholinergic effect Effects 0.000 claims description 2
229960001653 citalopram Drugs 0.000 claims description 2
229960003914 desipramine Drugs 0.000 claims description 2
229960004193 dextropropoxyphene Drugs 0.000 claims description 2
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 2
229960002866 duloxetine Drugs 0.000 claims description 2
229960002464 fluoxetine Drugs 0.000 claims description 2
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 2
229960001410 hydromorphone Drugs 0.000 claims description 2
229960004801 imipramine Drugs 0.000 claims description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
229960000905 indomethacin Drugs 0.000 claims description 2
229960003406 levorphanol Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
229960005118 oxymorphone Drugs 0.000 claims description 2
229960002296 paroxetine Drugs 0.000 claims description 2
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims description 2
229960005301 pentazocine Drugs 0.000 claims description 2
229960000482 pethidine Drugs 0.000 claims description 2
239000000952 serotonin receptor agonist Substances 0.000 claims description 2
229960002073 sertraline Drugs 0.000 claims description 2
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 2
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 2
229940102566 valproate Drugs 0.000 claims description 2
229960004688 venlafaxine Drugs 0.000 claims description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 2
229940072651 tylenol Drugs 0.000 claims 3
IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
239000004576 sand Substances 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
241000699670 Mus sp. Species 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
241000700159 Rattus Species 0.000 description 11
238000004458 analytical method Methods 0.000 description 9
230000002195 synergetic effect Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
241000282320 Panthera leo Species 0.000 description 8
239000000243 solution Substances 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
230000000694 effects Effects 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000009472 formulation Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000003292 diminished effect Effects 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
238000005304 joining Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
210000003497 sciatic nerve Anatomy 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
230000036592 analgesia Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
239000008213 purified water Substances 0.000 description 3
150000003873 salicylate salts Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
206010053552 allodynia Diseases 0.000 description 2
239000000969 carrier Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
239000010949 copper Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000011521 glass Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000002411 thermogravimetry Methods 0.000 description 2
ZCZQDTUCMRSEAS-DHDLBFDBSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n-(4-hydroxyphenyl)acetamide;phosphoric acid Chemical compound OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZCZQDTUCMRSEAS-DHDLBFDBSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
MBNMSERYORMPIB-UHFFFAOYSA-N 2-acetyloxybenzoic acid;calcium Chemical compound [Ca].CC(=O)OC1=CC=CC=C1C(O)=O MBNMSERYORMPIB-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
206010049589 Afterbirth pain Diseases 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000006561 Cluster Headache Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
208000004983 Phantom Limb Diseases 0.000 description 1
206010056238 Phantom pain Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000004550 Postoperative Pain Diseases 0.000 description 1
206010061363 Skeletal injury Diseases 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000003674 animal food additive Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
229960000991 ketoprofen Drugs 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
201000005518 mononeuropathy Diseases 0.000 description 1
230000007659 motor function Effects 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000012066 reaction slurry Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229960004025 sodium salicylate Drugs 0.000 description 1
JZLOKWGVGHYBKD-UHFFFAOYSA-M sodium;2-acetyloxybenzoate Chemical compound [Na+].CC(=O)OC1=CC=CC=C1C([O-])=O JZLOKWGVGHYBKD-UHFFFAOYSA-M 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
229950001675 spiperone Drugs 0.000 description 1
230000008925 spontaneous activity Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000009498 subcoating Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
208000009935 visceral pain Diseases 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

AU25430/97A 1996-03-25 1997-03-24 Method for treating pain Ceased AU725556B2 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US1413096P	1996-03-25	1996-03-25
US1413296P	1996-03-25	1996-03-25
US1412996P	1996-03-25	1996-03-25
US1412896P	1996-03-25	1996-03-25
US60/014132		1996-03-25
US60/014130		1996-03-25
US60/014128		1996-03-25
US60/014129		1996-03-25
PCT/US1997/004721 WO1997035586A1 (en)	1996-03-25	1997-03-24	Method for treating pain

Publications (2)

Publication Number	Publication Date
AU2543097A AU2543097A (en)	1997-10-17
AU725556B2 true AU725556B2 (en)	2000-10-12

Family

ID=27486362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU25430/97A Ceased AU725556B2 (en)	1996-03-25	1997-03-24	Method for treating pain

Country Status (16)

Country	Link
US (1)	US5945416A (2)
EP (1)	EP0921802A4 (2)
JP (1)	JP2000507945A (2)
CN (2)	CN1494907A (2)
AU (1)	AU725556B2 (2)
BR (1)	BR9708254A (2)
CA (1)	CA2250187A1 (2)
CZ (1)	CZ296263B6 (2)
EA (1)	EA000976B1 (2)
IL (1)	IL126203A (2)
NO (1)	NO318035B1 (2)
NZ (1)	NZ332039A (2)
PL (1)	PL187926B1 (2)
UA (1)	UA48219C2 (2)
WO (1)	WO1997035586A1 (2)
YU (1)	YU42198A (2)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9708246A (pt) *	1996-03-25	1999-07-27	Lilly Co Eli	Metodo para tratamento de dor
CA2250155A1 (en) *	1996-03-25	1997-10-02	Eli Lilly And Company	Anesthetic method
EP0906104A4 (en) *	1996-03-25	2003-12-10	Lilly Co Eli	PAIN TREATMENT PROCESS
ZA977967B (en) *	1996-09-23	1999-03-04	Lilly Co Eli	Combination therapy for treatment of psychoses
US20030133974A1 (en) *	1997-07-01	2003-07-17	Curatolo William John	Encapsulated solution dosage forms of sertraline
CA2290966C (en)	1997-07-01	2005-12-20	Pfizer Inc.	Sertraline salts and sustained-release dosage forms of sertraline
US20040208926A1 (en) *	1997-07-01	2004-10-21	Pfizer Inc	Solubilized sertraline compositions
US6960577B2 (en)	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
HUP0101901A3 (en) *	1998-05-22	2002-06-28	Lilly Co Eli	Pharmaceutical composition for combined therapeutic treatment of refractory depression and combined treating process
BR9911068A (pt) *	1998-05-29	2001-02-06	Lilly Co Eli	Terapia combinada para tratamento de distúrbios bipolares
SI1113797T1 (sl) *	1998-09-15	2010-02-26	Lilly Co Eli	Uporaba duloksetina pri zdravljenju fibromialgije
DE60022692T2 (de)	1999-07-01	2006-06-22	Pharmacia & Upjohn Co. Llc, Kalamazoo	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
PL365588A1 (en)	2000-07-21	2005-01-10	Teva Pharmaceutical Industries, Ltd.	Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DK1311256T3 (da) *	2000-08-17	2005-11-28	Teva Pharma	Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
US6602911B2 (en) *	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
EP1480629A1 (en) *	2002-02-08	2004-12-01	Abbott Laboratories	Combination therapy for treatment of schizophrenia
CA2475763A1 (en) *	2002-02-12	2003-08-21	Cypress Bioscience, Inc.	Methods of treating attention deficit/hyperactivity disorder (adhd)
CN1662231A (zh) *	2002-04-24	2005-08-31	柏树生物科学公司	包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US6881829B2 (en) *	2002-04-26	2005-04-19	Chimeracom, L.L.C.	Chimeric hybrid analgesics
WO2003101492A2 (en) *	2002-05-30	2003-12-11	Neurosearch A/S	Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
EP1558231A4 (en) *	2002-10-03	2010-09-08	Cypress Bioscience Inc	DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
MXPA05005609A (es) *	2002-11-26	2005-07-26	Alexza Pharmaceuticals Inc	Tratamiento de dolor de cabeza con antipsicoticos suministrados por inhalacion.
JP2006514934A (ja)	2002-11-26	2006-05-18	アレックザファーマシューティカルズ，インコーポレイテッド	疼痛治療用薬剤製造のためのロキサピンまたはアモキサピンの使用
KR100842694B1 (ko)	2002-12-27	2008-07-01	오쓰까 세이야꾸 가부시키가이샤	기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) *	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004105690A2 (en) *	2003-05-23	2004-12-09	Cypress Bioscience, Inc.	Treatment of chronic pain associated with drug or radiation therapy
US7531543B2 (en)	2003-10-14	2009-05-12	Wyeth	Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en)	2003-10-14	2009-02-17	Wyeth	Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en)	2003-10-14	2008-04-29	Wyeth	Substituted aryl cycloalkanol derivatives and methods of their use
US7524846B2 (en)	2003-10-14	2009-04-28	Wyeth	Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7550485B2 (en)	2003-10-14	2009-06-23	Wyeth	Substituted N-heterocycle derivatives and methods of their use
US7402698B2 (en)	2003-10-14	2008-07-22	Wyeth	Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en)	2003-10-14	2008-09-02	Wyeth	Fused-aryl and heteroaryl derivatives and methods of their use
DE102004011392A1 (de) *	2004-01-13	2005-08-04	Grünenthal GmbH	Schwache bis mittelstarke Opioide oder Kombinationen dieser Opioide mit Antidepressiva für die Behandlung von Depressionen, Angststörungen und Schmerzen
US7517899B2 (en)	2004-03-30	2009-04-14	Wyeth	Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en)	2004-03-30	2008-08-19	Wyeth	Phenylaminopropanol derivatives and methods of their use
TWI432196B (zh) *	2005-01-18	2014-04-01	Euro Celtique Sa	內臟痛的治療
US7994220B2 (en) *	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007062119A1 (en) *	2005-11-23	2007-05-31	Auspex Pharmaceuticals, Inc.	Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
US8551986B2 (en) *	2005-12-08	2013-10-08	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
WO2007096489A1 (fr) *	2006-02-17	2007-08-30	Trimaran Limited	Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US8536445B2 (en) *	2006-06-02	2013-09-17	Emcore Solar Power, Inc.	Inverted metamorphic multijunction solar cells
US20080102097A1 (en) *	2006-10-31	2008-05-01	Zanella John M	Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US20080031950A1 (en) *	2007-04-27	2008-02-07	Nectid Inc.	Novel anelgesic combination
US20080026054A1 (en) *	2007-04-27	2008-01-31	Nectid Inc.	Novel anelgesic combination
US8470360B2 (en)	2008-04-18	2013-06-25	Warsaw Orthopedic, Inc.	Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
WO2009126931A2 (en)	2008-04-11	2009-10-15	Xvasive, Inc.	Combination therapy for bipolar disorder
US9132085B2 (en)	2008-04-18	2015-09-15	Warsaw Orthopedic, Inc.	Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8946277B2 (en)	2008-04-18	2015-02-03	Warsaw Orthopedic, Inc.	Clonidine formulations in a biodegradable polymer carrier
US20090263451A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
USRE48948E1 (en)	2008-04-18	2022-03-01	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable polymer
US8956641B2 (en) *	2008-04-18	2015-02-17	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8557273B2 (en)	2008-04-18	2013-10-15	Medtronic, Inc.	Medical devices and methods including polymers having biologically active agents therein
US8420114B2 (en) *	2008-04-18	2013-04-16	Warsaw Orthopedic, Inc.	Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9072727B2 (en) *	2008-04-18	2015-07-07	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090264489A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8629172B2 (en)	2008-04-18	2014-01-14	Warsaw Orthopedic, Inc.	Methods and compositions for treating post-operative pain comprising clonidine
US8722079B2 (en)	2008-04-18	2014-05-13	Warsaw Orthopedic, Inc.	Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090263489A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US20090264477A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc., An Indiana Corporation	Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8883768B2 (en) *	2008-04-18	2014-11-11	Warsaw Orthopedic, Inc.	Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8889173B2 (en) *	2008-04-18	2014-11-18	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9132119B2 (en) *	2008-04-18	2015-09-15	Medtronic, Inc.	Clonidine formulation in a polyorthoester carrier
US9610243B2 (en)	2008-04-18	2017-04-04	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable polymer
US20100098746A1 (en) *	2008-10-20	2010-04-22	Warsaw Orthopedic, Inc.	Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) *	2008-12-01	2014-09-02	Medtronic, Inc.	Flowable pharmaceutical depot
US20100228097A1 (en) *	2009-03-04	2010-09-09	Warsaw Orthopedic, Inc.	Methods and compositions to diagnose pain
US20100239632A1 (en)	2009-03-23	2010-09-23	Warsaw Orthopedic, Inc.	Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) *	2009-07-17	2013-12-31	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) *	2009-07-31	2012-07-31	Warsaw Orthopedic, Inc.	Implantable drug depot for weight control
US20110097375A1 (en)	2009-10-26	2011-04-28	Warsaw Orthopedic, Inc.	Formulation for preventing or reducing bleeding at a surgical site
HUE065359T2 (hu)	2011-03-18	2024-05-28	Alkermes Pharma Ireland Ltd	Szorbitán-észtereket tartalmazó gyógyászati készítmények
GB2491118B (en)	2011-05-20	2015-12-30	Otsuka Pharma Co Ltd	Cannabinoids for use in the treatment of neuropathic pain
JP6219918B2 (ja)	2012-03-19	2017-10-25	アルカームスファーマアイルランドリミテッド	グリセロールエステルを含む医薬組成物
ES2765036T3 (es) *	2012-03-19	2020-06-05	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden esteres de ácidos grasos
ES2950418T3 (es)	2012-03-19	2023-10-09	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden alcohol bencílico
EP2897592B1 (en)	2012-09-19	2020-02-19	Alkermes Pharma Ireland Limited	Pharmaceutical compositions having improved storage stability
HRP20220112T1 (hr)	2013-12-24	2022-04-15	Virginia Commonwealth University	Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
WO2017218518A1 (en) *	2016-06-13	2017-12-21	Board Of Regents Of The University Of Texas System	Pharmaceutical compositions and methods for treatment of pain
EP3761983A1 (en)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
JP7614646B2 (ja)	2018-11-07	2025-01-16	ティアンリバイオテックプロプライエタリリミテッド	呼吸器疾患の処置のための化合物及び組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
DK203990D0 (da) *	1990-08-24	1990-08-24	Novo Nordisk As	Piperazinylderivater
US5605897A (en) *	1991-04-23	1997-02-25	Eli Lilly And Company	2-methyl-thieno-benzodiazepine
PT582368E (pt) *	1992-05-29	2001-05-31	Lilly Co Eli	Derivados de tienobenzodiazepina para o tratamento de doencas de cns
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
CZ298398A3 (cs) *	1996-03-25	1999-06-16	Eli Lilly And Company	Farmaceutický přípravek
CA2250155A1 (en) *	1996-03-25	1997-10-02	Eli Lilly And Company	Anesthetic method
BR9708246A (pt) *	1996-03-25	1999-07-27	Lilly Co Eli	Metodo para tratamento de dor

1997
- 1997-03-24 UA UA98095011A patent/UA48219C2/uk unknown
- 1997-03-24 JP JP9534530A patent/JP2000507945A/ja not_active Ceased
- 1997-03-24 CN CNA031556345A patent/CN1494907A/zh active Pending
- 1997-03-24 IL IL12620397A patent/IL126203A/en not_active IP Right Cessation
- 1997-03-24 CN CNB971949514A patent/CN1146421C/zh not_active Expired - Fee Related
- 1997-03-24 EP EP97916947A patent/EP0921802A4/en not_active Withdrawn
- 1997-03-24 BR BR9708254A patent/BR9708254A/pt not_active Application Discontinuation
- 1997-03-24 PL PL32921197A patent/PL187926B1/pl not_active IP Right Cessation
- 1997-03-24 EA EA199800857A patent/EA000976B1/ru not_active IP Right Cessation
- 1997-03-24 AU AU25430/97A patent/AU725556B2/en not_active Ceased
- 1997-03-24 US US08/823,461 patent/US5945416A/en not_active Expired - Fee Related
- 1997-03-24 WO PCT/US1997/004721 patent/WO1997035586A1/en not_active Ceased
- 1997-03-24 NZ NZ332039A patent/NZ332039A/en unknown
- 1997-03-24 CA CA002250187A patent/CA2250187A1/en not_active Abandoned
- 1997-03-24 CZ CZ0298298A patent/CZ296263B6/cs unknown
1998
- 1998-09-23 NO NO19984431A patent/NO318035B1/no unknown
- 1998-09-25 YU YU42198A patent/YU42198A/sh unknown

Also Published As

Publication number	Publication date
PL329211A1 (en)	1999-03-15
NO318035B1 (no)	2005-01-24
CA2250187A1 (en)	1997-10-02
CN1219877A (zh)	1999-06-16
CZ296263B6 (cs)	2006-02-15
IL126203A (en)	2002-12-01
EA199800857A1 (ru)	1999-02-25
CN1494907A (zh)	2004-05-12
US5945416A (en)	1999-08-31
WO1997035586A1 (en)	1997-10-02
NZ332039A (en)	2000-06-23
YU42198A (sh)	1999-09-27
BR9708254A (pt)	1999-08-03
NO984431L (no)	1998-11-19
EP0921802A1 (en)	1999-06-16
JP2000507945A (ja)	2000-06-27
PL187926B1 (pl)	2004-11-30
CZ298298A3 (cs)	1999-01-13
IL126203A0 (en)	1999-05-09
UA48219C2 (uk)	2002-08-15
EA000976B1 (ru)	2000-08-28
AU2543097A (en)	1997-10-17
CN1146421C (zh)	2004-04-21
NO984431D0 (no)	1998-09-23
EP0921802A4 (en)	2002-05-08

Legal Events

Date	Code	Title	Description
2000-11-16	SREP	Specification republished
2001-02-08	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU725556B2 (en)	2000-10-12	Method for treating pain
US6936601B2 (en)	2005-08-30	Compositions for treating pain
AU721338B2 (en)	2000-06-29	Method for treating pain
AU721290B2 (en)	2000-06-29	Method for treating migraine pain
AU734011B2 (en)	2001-05-31	Method for treating bipolar disorder
CA2250155A1 (en)	1997-10-02	Anesthetic method
CN101778632B (zh)	2012-02-29	综合失调症的治疗或预防药
HUP9903375A2 (hu)	2000-02-28	Olanzapint és fájdalomcsillapító hatóanyagot tartalmazó szinergista hatású gyógyszerkészítmények
EP1007041A1 (en)	2000-06-14	Composition for treating pain
KR20000004965A (ko)	2000-01-25	통증 치료 방법
AU724245B2 (en)	2000-09-14	Method for treating insomnia
AU725940B2 (en)	2000-10-26	Method for treating substance abuse
KR19990087716A (ko)	1999-12-27	과도한 공격성의 치료 방법
KR20000004964A (ko)	2000-01-25	통증 치료 방법
HUP9903183A2 (hu)	2000-02-28	Olanzapin alkalmazása fájdalomcsillapító hatású gyógyszerkészítmények előállítására